Please ensure Javascript is enabled for purposes of website accessibility
ORIGINAL ARTICLE
Malignant transformation of low-risk choroidal nevi: a case series
 
More details
Hide details
1
Department of Ophthalmology, Poznan University of Medical Sciences, Poznan, Poland
 
2
Faculty of Biology and Medicine of the University of Lausanne, Jules Gonin Hospital, Lausanne, Switzerland
 
 
Submission date: 2025-07-29
 
 
Final revision date: 2025-10-06
 
 
Acceptance date: 2025-10-06
 
 
Online publication date: 2026-10-19
 
 
Corresponding author
Iwona Rospond-Kubiak   

Department of Ophthalmology, Poznan University of Medical Sciences, Poznan, Poland
 
 
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
A well documented transformation from a choroidal nevus to melanoma is uncommon.

Aim of the research:
To report a series of choroidal melanocytic lesions diagnosed at the Ocular Oncology Service, Department of Ophthalmology, Poznan University of Medical Studies, Poland, presenting initially low-risk features for malignancy, which transformed into choroidal melanomas.

Material and methods:
Retrospective data analysis of patients with choroidal nevi without major features for growth (thickness over 2 mm in ultrasound (US), subretinal fluid (SRF), orange pigment). Lesions were evaluated at all visits using multimodal imaging (colour and autofluorescence fundus photography, OCT, and US measurements) until the melanoma diagnosis. We measured alterations in thickness, growth rate (GR) and tumour doubling time (TDT) and across the consecutive visits.

Results:
We identified 11 lesions with a median thickness of 0.95 mm at presentation (range: 0.3–1.9 mm). The median observation time until transformation was 47 months (range: 17–99 months). Ten (91%) lesions showed lipofuscin accumulation, 8 (73%) grew in thickness over 2 mm in US, 8 (73%) were diagnosed with SRF and 6 (54%) extended in their longitudinal diameter. The median overall GR was 0.67 mm/year (range: 0.0–3.4 mm/year) and the median overall TDT was 884 days (range: 167–3719 days). On follow-up, majority of lesions presented heterogenous GR and TDT, and at the time of fastest growth, median GR was 1.88 mm/year (range: 0.0–5.6 mm/year) and median TDT was 201 days (range: 83–3044 days).

Conclusions:
Choroidal nevus may transform into choroidal melanoma after years of stability and therefore should undergo a regular follow-up. Careful monitoring of GR and TDT may aid the diagnosis of malignant transformation.
REFERENCES (32)
1.
Ng CH, Wang JJ, Mitchell P, Amirul Islam FM, Wong TY. Prevalence and characteristics of choroidal nevi in an Asian vs white population. Arch Ophthalmol. 2009; 127: 314-319.
 
2.
Greenstein MB, Myers CE, Meuer SM, Klein BEK, Cotch MF, Wong TY, Klein R. Prevalence and characteristics of choroidal nevi: the multi-ethnic study of atherosclerosis. Ophthalmology. 2011; 118: 2468-2473.
 
3.
Jonas JB, You QS, Xu L, Wang YX. Choroidal nevi in adult Chinese. Ophthalmology. 2008; 115: 1102-1102.e1.
 
4.
Sumich P, MItchell P, Wang JJ. Choroidal nevi in a white population: the Blue Mountains Eye Study. Arch Ophthalmol. 1998; 116: 645-650.
 
5.
Nangia V, Jonas JB, Agarwal S, Khare A, Lambat S, Panda- Jonas S. Choroidal nevi in adult Indians: the Central India Eye and Medical Study. Br J Ophthalmol. 2012; 96: 1443.1-1444.
 
6.
Qiu M, Shields CL. Choroidal nevus in the United States adult population. Ophthalmology. 2015; 122: 2071-2083.
 
7.
Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, Lutz JM, Paci E; EUROCARE Working Group. Incidence of uveal melanoma in Europe. Ophthalmology. 2007; 114: 2309-2315.
 
8.
Singh AD, Kalyani P, Topham A. Estimating the risk of malignant transformation of a choroidal nevus. Ophthalmology. 2005; 112: 1784-1789.
 
9.
Shields CL, Shields JA, Kiratli H, De Potter P, Cater JR. Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology. 1995; 102(9): 1351-1361.
 
10.
Roelofs KA, O’day R, Harby LA, Arora AK, Cohen VML, Sagoo MS, Damato B. The moles system for planning management of melanocytic choroidal tumors: is it safe? Cancers. 2020; 12: 1311.
 
11.
Al Harby L, Sagoo MS, O’Day R, Hay G, Arora AK, Keane PA, Cohen VML, Damato B. Distinguishing choroidal nevi from melanomas using the MOLES algorithm: evaluation in an ocular nevus clinic. Ocul Oncol Pathol. 2021; 7: 294-302.
 
12.
Damato BE. Can the MOLES acronym and scoring system improve the management of patients with melanocytic choroidal tumours? Eye. 2023; 37: 830-836.
 
13.
Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, Kelly CC, Rudich DS, Nagori AV, Wakade OA, Mehta S, Forte L, Long A, Dellacava EF, Kaplan B, Shields JA. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009; 127: 989-998.
 
14.
Spaide RF, Koizumi H, Pozonni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol. 2008; 146: 496-500.
 
15.
Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol. 2009; 147: 811-815.
 
16.
Rahman W, Chen FK, Yeoh J, Patel P, Tufail A, Da Cruz L. Repeatability of manual subfoveal choroidal thickness measurements in healthy subjects using the technique of enhanced depth imaging optical coherence tomography. Investig Opthalmol Vis Sci. 2011; 52: 2267-2271.
 
17.
Stålhammar G, Coupland SE, Ewens KG, Ganguly A, Heimann H, Shields CL, Damato B. Improved staging of ciliary body and choroidal melanomas based on estimation of tumor volume and competing risk analyses. Ophthalmology. 2024; 131: 478-491.
 
18.
Shields CL, Furuta M, Berman EL, Zahler JD, Hober- man DM, Dinh DH, Mashayekhi A, Shields JA. Choroidal nevus transformation into melanoma. Arch Ophthalmol. 2009; 127: 981-987.
 
19.
Weber C, Herwig-Carl MC, Boeker A, Holz FG, Liegl R. Transformation eines Aderhautnävus in ein Aderhautmelanom nach Jahrzehnten. Ophthalmol. 2023; 120: 841-846.
 
20.
Jouhi S, Al-Jamal RT, Täll M, Eskelin S, Kivelä TT. Presumed incipient choroidal melanoma: proposed diagnostic criteria and management. Br J Ophthalmol. 2023; 107: 412-417.
 
21.
Oakey Z, Yeşiltaş YS, Zabor EC, Singh AD. Growth of indeterminate choroidal melanocytic tumors: time to malignant transformation. Taiwan J Ophthalmol. 2025; 15: 73-78.
 
22.
Sahel JA, Pesavento R, Frederick AR, Albert DM. Melanoma arising de novo over a 16-month period. Arch Ophthalmol. 1988; 106: 381-385.
 
23.
Aleksidze N, Medina CA, Singh AD. De novo evolution of a small choroidal melanoma. Ocul Oncol Pathol. 2015; 1: 83-87.
 
24.
Singh AD, Grossniklaus HE. What’s in a name? Large choroidal nevus, small choroidal melanoma, or indeterminate melanocytic tumor. Ocul Oncol Pathol. 2021; 7: 235-238.
 
25.
Augsburger JJ, Gonder JR, Amsel J, Shields JA, Donoso LA. Growth rates and doubling times of posterior uveal melanomas. Ophthalmology. 1984; 91: 1709-1715.
 
26.
Gass J, Donald M. Comparison of uveal melanoma growth rates with mitotic index and mortality. Arch Ophthalmol. 1985; 103: 924-931.
 
27.
Char DH, Kroll S, Phillips TL. Uveal melanoma: growth rate and prognosis. Arch Ophthalmol. 1997; 115: 1014-1018.
 
28.
Jouhi S, Jager MJ, De Geus SJR, Desjardins L, Eide NA, Grange JD, Kiilgaard JF, Seregard S, Midena E, Parrozza- ni R, Caujolle JP, Rospond-Kubiak I, Kivelä TT. The small fatal choroidal melanoma study. a survey by the European Ophthalmic Oncology Group. Am J Ophthalmol. 2019; 202: 100-108.
 
29.
Stålhammar G, Hagström A, Ermedahl Conradi M, Williams PA. Choroidal nevi and melanoma doubling times and implications for delays in treatment: a systematic review and meta-analysis. Surv Ophthalmol. 2025; 70: 38-46.
 
30.
Mashayekhi A, Siu S, Shields CL, Shields JA. Slow enlargement of choroidal nevi: a long-term follow-up study. Ophthalmology. 2011; 118: 382-388.
 
31.
Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T. Tumor doubling times in metastatic malignant melanoma of the uvea. Ophthalmology. 2000; 107: 1443-1449.
 
32.
Barbagallo C, Stella M, Broggi G, Russo A, Caltabiano R, Ragusa M. Genetics and RNA regulation of uveal melanoma. Cancers. 2023; 15: 775.
 
eISSN:2300-6722
ISSN:1899-1874
Journals System - logo
Scroll to top